Agmatine Sulfate
Neuromodulator, Mood
Described as having a short plasma half-life, but no reliable numeric human value is available. Agmatine is also produced endogenously, which complicates any single figure.
In short
- A decarboxylated arginine metabolite that is genuinely produced endogenously and acts as a neuromodulator.
- Sold as a dietary supplement, most often for neuropathic pain and mood.
- The strongest human evidence is a small trial in lumbar disc-associated radiculopathy.
- Frequently marketed as a nitric oxide booster for pumps, which is mechanistically backwards — it INHIBITS nitric oxide synthase.
- Very short plasma half-life; large oral doses are commonly used to compensate.
Structure
How it works
Agmatine is formed by decarboxylation of arginine and is present in the brain, where it is stored in synaptic vesicles and released on depolarisation — the criteria for a neurotransmitter.
Its described actions are numerous: agonism at imidazoline receptors, antagonism at NMDA receptors, inhibition of nitric oxide synthase, and modulation of alpha-2 adrenergic receptors.
The NMDA antagonism and imidazoline activity underlie the neuropathic pain and mood interest. The NOS inhibition is worth noting precisely because agmatine is often sold as a nitric oxide enhancer for training pumps — the mechanism points the other way.
What the research shows
A randomised placebo-controlled trial in patients with lumbar disc herniation and radiculopathy reported improvement in pain and quality of life over two weeks — the best human evidence available for it.
Animal studies support antinociceptive, anxiolytic, and antidepressant-like effects reasonably consistently, and show potentiation of morphine analgesia with reduced tolerance development.
Evidence for performance, pumps, or muscle growth is absent.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — randomised trial in lumbar radiculopathy | 2.67 g daily for 14 days | oral | PubMed |
| Human — tolerability studies | Up to 3.6 g daily reported tolerated | oral | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 500 mg–1.5 g daily | oral |
The trial dose of 2.67 g daily is substantially higher than typical supplement dosing. Gastrointestinal tolerance is the practical limit, and the short half-life means divided dosing is common.
Handling and storage
Oral, as capsules or powder. Frequently taken in divided doses given the short plasma half-life.
Commonly taken on an empty stomach, though gastrointestinal upset at higher doses is the main reason people take it with food.
Side effects
Generally well tolerated. The most common issues are gastrointestinal — nausea, diarrhoea, and discomfort, all dose-related.
Mild blood pressure reduction has been reported, consistent with imidazoline receptor activity.
Long-term human safety data is limited; the trial evidence covers weeks rather than years.
Because it inhibits nitric oxide synthase, taking it expecting a vasodilatory pump effect is likely to be counterproductive as well as ineffective.
Combinations
Commonly combined with opioids in the animal literature, where it potentiated analgesia and attenuated tolerance — a genuinely interesting finding but one without human trial support.
Combining with NMDA-active compounds or with other blood-pressure-lowering agents is the theoretically relevant caution.
Research status
A substantial preclinical literature on agmatine as a neuromodulator, spanning pain, mood, and neuroprotection.
Human clinical work is much thinner — the radiculopathy trial is the standout, and it is small.
Legal status
Sold as a dietary supplement in the US and many other jurisdictions. Not approved as a drug for any indication.
WADA status
Not on the WADA Prohibited List. Sold as a dietary supplement, so the S0 unapproved-substance clause does not apply. Supplement contamination remains the practical doping risk, and third-party batch testing is the only real mitigation.
Conclusion
Agmatine has more genuine neuropharmacology behind it than most supplements and a single decent human trial, in neuropathic pain, at a dose most people do not take.
The pre-workout marketing is the part to disregard: it inhibits nitric oxide synthase, which is the opposite of what the pump claim requires.
Sources
Track your own Agmatine Sulfate protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.